Effect of advanced glycosylation end products on activity of protein kinase C in human peripheral blood mononuclear cells

( views:58, downloads:0 )
Author:
TONG Jiay()
LJU Naifeng()
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 113, Issue 12, 2000
DOI:
Key Word:
advanced glycosylation end products;protein kinase C;mononuclear cells;aminoguanidine signal transduction

Abstract: Objectives TO investigate the effect of advanced glycosylation end products (AGEs) on the activity of protein kinese C (PKC) in human peripheral bloodmononuclear Cells (PBMC) and to observe whether aminoguanidine (AG) can influence the effect of AGEs. Methods After PBMC were isoiated from human peripheral blood and incubated with different concentrations of AGEs-BSA for various periods, total PKC activity in PBMC was determined by measuring the incorporation of 32P from [γ-32P] ATP=into a special substrate using Prornega PKC assay kit. Results AGEs-BSA increased the total PKC activity in PBMC from 83.43±6.57 pmol/min/mg protein to 116.8±13.82 pmol/min/mg protein with a peak at 15 min.AGEs-BSA also increased the total PKC activity in a concentration-dependent manner from 83.1±6.4 pmol/min/mg protein(control) to 119.1±13.3 pmol/min/mg protein (control vs AGEs-BSA 400 mg/L, P<0.01). Furthermore, AGEs-BSA induced an elevation of PKC activity in a glycosylating time-related manner,from 80.9±8.2 (control) to 118.3±11.5 pmol/min/mg protein (glycasytation for 12 wk, P<0.01). The total PKC activity stimulated by AGEs-BSA pretreated with AG (100, 200 mg/L) was markedly lower than that of AGEs-BSA group not pretreated with AG ( P<0.05, P<0.01). Conclusions AGEs-BSA increased the total PKC activity in PBMC in a concentration and incubation time dependent manner. The ability of AGEs-B.SA to stimulate PKC activity was markedly decreased by pretreatment of AGEs-BSA with AG.

  • 1.Shantaram V.Pathogenesis of atherosclerosis in diabetes and hypertension.Clin Exp Hypertension 1999;21:69-77.
  • 2.Pamplona R,Bellmunt MJ,Portero M,et al.Mechanism of glycation in atherogenesis.Med Hypotheses 1993;40:174-181.
  • 3.Neeper M,Schmidt AM,Brett J,et al.Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.J Biol Chem 1992;267:14998-15004.
  • 4.Brett J,Schmidt AM,Yan SD,et al.Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.Am J Pathol 1993;143:1699-1712.
  • 5.Schmidt AM,Yan SD,Brett J,et al.Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;91:2155-2168.
  • 6.Brownlee M,Vlassara H.Glycation and diabetic complication.Diabetes 1994;43:836-841.
  • 7.Bucala R,Vlassara H.Advanced glycosylation end products indiabetic renal and vascular disease.Am J Kidney Dis 1995;26:875-887.
  • 8.Vlassara H.Recent progress on the biologic and clinical significance of advanced glycation end products.J Lab Clin Med 1994;124:19-30.
  • 9.Kaisuke K,George LK.Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
  • 10.Brownlee M.Glycation and diabetic complications.Diabetes 1994;43:836-841.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn